Markers of acute kidney failure

Abstract

The present invention relates to a method of determining the risk of acute kidney injury comprising determining the amount of a marker selected from VCAN, NRP1, CCL2, CCL19, COL3A1, GZMM or any combination thereof in a sample.

1 . A method of determining the risk for acute kidney injury disease in a patient comprising the steps of:
 measuring a concentration of at least one kidney risk factor (KRF) in a sample from said patient;   comparing the measured KRF concentration to a control value; and   determining the patient's risk of acute kidney injury based on comparing the measured KRF concentration to the control value,   wherein the at least one KRF is a predictor of disease progression and is selected from the group consisting of VCAN, NRP1, CCL2, CCL19, COL3A1 and GZMM, and   wherein the patient is suffering from a chronic disease selected from the group consisting of diabetes, hypertension, and heart disease.   
     
     
         2 . The method of  claim 1 , wherein the level of the KRF is at least 1.2 times increased compared to a control. 
     
     
         3 . The method of  claim 1 , wherein the area under a ROC curve associated with the KRF is at least 0.8 using the Somer's D statistic. 
     
     
         4 . The method of  claim 1 , wherein the expression of KRF is determined in the sample. 
     
     
         5 . The method of  claim 1 , wherein a polypeptide or polynucleotide level of the KRF is determined. 
     
     
         6 . The method according to  claim 1 , wherein the sample is selected from the group consisting of tissue, blood, serum, plasma and a urine sample. 
     
     
         7 . The method of  claim 1 , wherein the patient is suffering from a chronic disease, optionally diabetes, hypertension and heart disease. 
     
     
         8 . The method of  claim 1 , wherein the patient is tested before receiving nephrotoxic medication. 
     
     
         9 . The method of  claim 1 , wherein the KRF is determined by microarray hybridization with specific probes or by PCR. 
     
     
         10 . A panel of markers for determining acute renal failure, consisting of at least two markers selected from the group consisting of VCAN, NRP1, CCL2, CCL19, COL3A1 and GZMM. 
     
     
         11 . A set of reagents for determining acute renal failure, wherein the reagents detect at least two markers of the panel according to  claim 10 . 
     
     
         12 . The set of  claim 11 , wherein the reagents are ligands specifically binding to the markers. 
     
     
         13 . The set of  claim 12 , wherein the ligands are nucleotide sequence specific oligonucleotides. 
     
     
         14 . The set of  claim 12 , wherein the ligands are antibodies or antibody fragments. 
     
     
         15 . The set of  claim 11 , wherein the reagents are labeled.